Fig. 2From: A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancerBest tumor shrinkage based on tyrosine-protein kinase Met expression. IHC immunohistochemial analysisBack to article page